

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Withdrawn) A minibody that recognizes a human leukocyte antigen (HLA).
2. (Withdrawn) The minibody of claim 1, wherein the HLA is an HLA class I.
3. (Withdrawn) The minibody of claim 2, wherein the HLA class I is an HLA-A.
4. (Withdrawn) A minibody derived from a 2D7 antibody.
5. (Withdrawn) The minibody of any one of claims 1 to 4, wherein the minibody is a diabody.
6. (Withdrawn) A minibody of any one of (a) to (d):
 - (a) a minibody comprising the amino acid sequence of SEQ ID NO: 6;
 - (b) a minibody functionally equivalent to the minibody of (a), and comprising an amino acid sequence with a substitution, insertion, deletion and/or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 6;
 - (c) a minibody comprising the amino acid sequences of CDRs of SEQ ID NOs: 2 and 4; and
 - (d) a minibody functionally equivalent to the minibody of (c), and comprising an amino acid sequence with a substitution, insertion, deletion and/or addition of one or more amino acids in the amino acid sequence of the CDRs of SEQ ID NOs: 2 and 4.

7. - 12. (Canceled)

13. (Withdrawn) A cell death-inducing agent, comprising as an active ingredient the minibody of any one of claims 1 to 6, the minibody produced by the method of any one of claims 7 to 12, or a 2D7 antibody.

14. (Withdrawn) The cell death-inducing agent of claim 13 that induces cell death of a B cell or T cell.

15. (Withdrawn) The cell death-inducing agent of claim 14, wherein the B cell or T cell is an activated B cell or activated T cell.

16. (Withdrawn) A cell growth-suppressing agent comprising as an active ingredient the minibody of any one of claims 1 to 6, the minibody produced by the method of any one of claims 7 to 12, or a 2D7 antibody.

17. (Withdrawn) An antitumor agent comprising as an active ingredient the minibody of any one of claims 1 to 6, the minibody produced by the method of any one of claims 7 to 12, or a 2D7 antibody.

18. (Withdrawn) The antitumor agent of claim 17, wherein the tumor is a blood tumor.

19. (Withdrawn) A therapeutic agent for an autoimmune disease, wherein the therapeutic agent comprises as an active ingredient the minibody of any one of claims 1 to 6, the minibody produced by the method of any one of claims 7 to 12, or a 2D7 antibody.

20. (Withdrawn) The cell death-inducing agent of any one of claims 13 to 15, wherein the antibody is a diabody.

21. (Withdrawn) The cell growth-suppressing agent of claim 16, wherein the antibody is a diabody.

22. (Withdrawn) The antitumor agent of claim 17 or 18, wherein the antibody is a diabody.

23. (Withdrawn) The therapeutic agent for autoimmune disease of claim 19, wherein the antibody is a diabody.

24. (Currently amended) A method for producing an HLA-A antigen-recognizing minibody, the method comprising:

- (a) identifying a whole antibody that recognizes a domain selected from the group consisting of domain $\alpha 1$ and domain $\alpha 2$ of an HLA-A antigen;
 - (b) producing a minibody version of the antibody of (a); and
 - (c) assaying a cytotoxic activity of the minibody,
- wherein the minibody is an scFv or a diabody.

25. (Previously presented) The method of claim 24, further comprising:

- (d) determining whether the minibody has an increased cytotoxic activity compared to the antibody of (a).

26. - 27. (Canceled)

28. (Previously presented) The method of claim 24, wherein the antibody of (a) is an IgG.

29. - 30. (Canceled)

31. (Previously presented) The method of claim 24, wherein the scFv or the diabody comprises CDRs derived from a heavy chain variable region and a light chain variable region of the antibody of (a).

32. (Previously presented) The method of claim 24, wherein the minibody is a diabody comprising two scFv.

33. (Previously presented) The method of claim 24, wherein the cytotoxic activity is a cell death-inducing activity.

34. (Previously presented) The method of claim 24, wherein the cytotoxic activity is a cell growth-suppressing activity.

35. (Currently amended) A method of producing a minibody, the CDRs of which are derived from the CDRs of a whole antibody that recognizes a domain selected from the group consisting of domain $\alpha 1$ and domain $\alpha 2$ of an HLA-A antigen, wherein the minibody has a level of cytotoxic activity greater than that of the whole antibody, the method comprising:

- (a) providing a DNA encoding the minibody;
 - (b) expressing the minibody from the DNA; and
 - (c) confirming that the expressed minibody possesses cytotoxic activity greater than that of the whole antibody,
- wherein the minibody is an scFv or a diabody.

36. (Previously presented) The method of claim 35, wherein the minibody comprises human framework regions.

37. (Previously presented) The method of claim 35, wherein the whole antibody is a human antibody.

38. (Previously presented) The method of claim 35, wherein the whole antibody is a non-human antibody and the minibody is humanized.

39. – 41. (Canceled)

42. (Previously presented) The method of claim 35, wherein the cytotoxic activity is a cell death-inducing activity.

43. (Previously presented) The method of claim 35, wherein the cytotoxic activity is a cell growth-suppressing activity.

44. (Previously presented) An HLA-recognizing scFv or diabody produced by the method of claim 35.

45. (Previously presented) An HLA-recognizing minibody produced by the method of claim 24.